Last reviewed · How we verify
NCT04537975
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19
NA trial testing C2Rx in Continuous Renal Replacement Therapy. Withdrawn.
15 November 2020
Quick facts
| Lead sponsor | SeaStar Medical |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 15 September 2020 |
| Primary completion | 15 November 2020 |
| Estimated completion | 15 January 2021 |
Drugs / interventions tested
- C2Rx
- Standard of Care (SOC) — full drug profile →
Conditions studied
- Continuous Renal Replacement Therapy — all drugs for Continuous Renal Replacement Therapy →
- Pulmonary Edema — all drugs for Pulmonary Edema →
- COVID-19 — all drugs for COVID-19 →
Sponsor
SeaStar Medical — full company profile →
Who can join
Adults 18 to 80, any sex, with Continuous Renal Replacement Therapy or Pulmonary Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method.
Nasa P, Azoulay E, Khanna AK, Jain R, et al · · 2021 · cited 126× · PMID 33726819 · DOI 10.1186/s13054-021-03491-y
Verify or expand the search:
- PubMed search for NCT04537975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Continuous Renal Replacement Therapy
Currently open trials in the same condition.
- NCT07293936 — Post-Filter Hematocrit · NA · recruiting
- NCT06369064 — Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Car · NA · recruiting
- NCT06021080 — Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagu · recruiting
- NCT04114747 — Renal Physiology During Continuous Renal Replacement Therapy · NA · recruiting
- NCT03897582 — Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study · recruiting
Other SeaStar Medical trials
Trials by the same sponsor.
- NCT04395911 — Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04537975 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SeaStar Medical
- Last refreshed: 14 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing